MedPath

Swiss Cardio Technologies AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:4
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 3
1 (25.0%)

Observational Study to Investigate the Effects of Training on the Administration of Cardioplexol™

Phase 3
Completed
Conditions
Coronary Artery Bypass Surgery
Valve Surgery
Interventions
Drug: Cardioplegia Solution
First Posted Date
2019-01-30
Last Posted Date
2021-10-21
Lead Sponsor
Swiss Cardio Technologies AG
Target Recruit Count
171
Registration Number
NCT03823521
Locations
🇦🇹

Universitätsklinik Innsbruck, Innsbruck, Austria

🇦🇹

Universitaetsklinikum Salzburg, Salzburg, Austria

🇦🇹

Universitaetsklnikum St. Pölten, St. Pölten, Austria

and more 3 locations

News

Cardioplexol™ Demonstrates Safety and Efficacy in Phase 3 Trial for Cardiac Surgery

A pivotal phase 3 non-inferiority trial has confirmed the safety and efficacy of Cardioplexol™, a new low-volume cardioplegic solution, compared to standard Buckberg blood cardioplegia in cardiac surgeries.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.